The GLP-1 conversation has collapsed into a single word: Ozempic. That is a brand name. The molecules underneath it are a small, evolving family of drugs, and they do not behave the same way.
This piece is the version of the explainer we wish existed when men first ask us about "the weight loss shot." No marketing copy. No Reddit folklore. Just what the data says and how a Vane clinician actually thinks about which option fits which patient.
What is a GLP-1 medication?
A GLP-1 (glucagon-like peptide-1) medication is an injectable peptide that mimics gut hormones your body already produces after eating. The effects are:
- Slowed gastric emptying, which makes you feel full longer.
- Better insulin response to food, which smooths post-meal blood sugar.
- Reduced appetite signaling, both centrally and peripherally.
The newer drugs in the class do more than just GLP-1 mimicry. They layer on other gut hormones with their own effects. Same family, different members.
The three GLP-1 medications men ask about
| Medication | Hormones it mimics | Brand names | Status |
|---|---|---|---|
| Semaglutide | GLP-1 only | Ozempic, Wegovy, Rybelsus | FDA approved |
| Tirzepatide | GLP-1 + GIP | Mounjaro, Zepbound | FDA approved |
| Retatrutide | GLP-1 + GIP + glucagon | None yet | Phase 3 trials |
GLP-1 alone (semaglutide) is appetite suppression plus slowed gastric emptying plus better post-meal insulin response. Adding GIP (tirzepatide) layers in better insulin sensitivity and cleaner body-composition change in trials. Adding glucagon agonism (retatrutide) lights up hepatic fat metabolism, with the strongest absolute weight effect of the three in early data.
How do GLP-1s work for weight loss?
The mechanism is mostly upstream of "less food." GLP-1 receptor activation reduces hunger signals in the hypothalamus and brainstem. Slowed gastric emptying means each meal feels larger. The combined effect is a sustained, low-grade calorie reduction that most patients describe as "I stopped thinking about food" rather than "I am dieting."
In trials, the average weight loss over 68 weeks at maximum dose:
- Semaglutide 2.4 mg/week: about 15% of body weight.
- Tirzepatide 15 mg/week: about 21% of body weight.
- Retatrutide 12 mg/week (Phase 2 data): about 24% of body weight.
Those numbers come from patients with BMI of 30 or higher. The picture changes for the men we work with.
Why dose is the more interesting question
Most consumer-facing articles repeat the obesity-trial doses. Those were the doses that maximized weight loss in trials with severely overweight patients.
Most of the men in our clinic are not there. They are 28% body fat, lean-mass-conscious, performance-oriented. They want the metabolic signal of a GLP-1 (appetite regulation, post-meal glucose smoothing, lower visceral fat) without the side effects that come with chasing the maximum dose.
That is the GLP-1 microdose conversation. The dosing range used by the trial designers is wider than the marketed dose. A 0.25 to 0.5 mg/week semaglutide protocol behaves differently than a 2.4 mg/week protocol. Same drug, same mechanism, different chapter.
We cover that protocol in detail in the GLP-1 microdose piece. For now: if you have been told "you start at X mg and titrate to Y mg, that is the protocol," that protocol was written for a different patient.
The muscle-loss problem
The headline number in every trial is total weight lost. The number that matters for a 38-year-old man is what he lost.
GLP-1s reduce calorie intake. A meaningful share of weight lost on any sustained calorie deficit is lean mass. That is gravity, not the drug's fault. But you can stack the deck:
- Protein: 1.6 g/kg of bodyweight as a floor, not a ceiling.
- Resistance training: three sessions a week, progressive. Cardio is fine but not the lever.
- Loss rate: faster weight loss equals more lean mass given up. About 0.5%/week of bodyweight is the upper edge of "mostly fat."
- Dose: the obesity-trial doses drive rapid weight loss. Microdosing slows that down by design.
We cover this in depth in Muscle loss on GLP-1s. The short version: the drug does not decide what you lose. The protocol does.
What the clinician actually checks
Before we would put a man on any GLP-1, we look at the panel. Not the BMI.
Markers we check before a GLP-1 starts
- Fasting insulin is the cleanest early signal of insulin resistance, often before A1c moves.
- ApoB is the lipid number that correlates with cardiovascular event risk better than LDL alone.
- Visceral fat (DEXA preferred, BIA acceptable) distinguishes the man who needs a GLP-1 from the man who needs a different lever entirely.
- Liver enzymes plus GGT changes the calculus toward retatrutide-class molecules if fatty liver is present.
- Thyroid panel rules out endocrine causes of weight gain masquerading as metabolic disease.
- Testosterone (free plus total) matters because low T flattens the calorie-deficit response. You fix the upstream problem first.
Side effects that actually matter
Early-week nausea is real and well-documented. It is not the side effect that should drive your decision.
The conversations worth having:
- Gastroparesis risk. Most men tolerate slowed gastric emptying. A subset develops more persistent symptoms. Reversible on cessation. Not zero risk.
- Gallbladder issues. Meaningful absolute risk increase with rapid weight loss. Higher with faster loss.
- Sarcopenia (muscle loss). Covered above. Not on the side-effect leaflet because it is a function of how you use the drug, not the drug itself.
- Mental health signals. Early reports flagged mood effects in some patients. Later analyses have been more reassuring. We check baseline mood and we ask at follow-ups.
How long does it take to work?
Appetite usually shifts within the first week or two. Weight movement is measurable by week 4. Body composition change (fat down, muscle preserved or up) takes 3 to 6 months when the protocol is built right. Most of the men we work with run a 6 to 12 month course, then taper.
Who should not take a GLP-1?
We do not prescribe GLP-1s for:
- Personal or family history of medullary thyroid carcinoma or MEN-2.
- Active or prior pancreatitis.
- Pregnancy or planned pregnancy in the next 8 weeks.
- Severe gastroparesis or gastric outlet obstruction.
- BMI below 22 without a metabolic indication, in most cases.
This is not the full list. A clinician will go through your history before any prescription is written.
Where Vane lands
The men we work with want the metabolic effect without becoming a different version of themselves. That means:
- Right molecule for the metabolic signature, not for the marketing.
- Right dose, almost always lower than the consumer ads suggest.
- Stacked protocol where resistance training and protein are non-negotiable, not optional.
- Panel reread quarterly, including ApoB, fasting insulin, lean mass, liver enzymes. The shot is one variable in a system.
GLP-1s are one of the highest-leverage tools in this generation of men's medicine. They are also the tool most likely to be used wrong. The difference is upstream of the drug.
If you are considering starting, we would rather you start with a panel than with a prescription.
